전이성 폐 선암 치료 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 흡연 및 환경 요인의 증가, 새로운 약물 치료법의 승인 증가, 신흥 시장의 의료 인프라 확대, 개인 맞춤형 의학 접근법의 증가, 제약 회사와 연구 기관 간의 협력 확대에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 액체 생검 기술의 발전, 더 나은 결과를 위한 첨단 복합 치료법 개발, 표적 약물 전달 시스템의 혁신, 정밀 치료를 위한 AI 기반 진단 기술의 발전, 면역 종양학 치료의 발전 등이 있습니다.
표적 치료의 채택이 증가함에 따라 전이성 폐 선암 치료 시장이 성장할 것으로 예상됩니다. 표적 치료는 종양의 발생과 확산을 촉진하는 특정 유전자 또는 단백질을 표적으로 하는 약물을 사용하여 암의 성장을 차단합니다. 이 접근법은 특정 유전자 변이를 표적으로 하기 때문에 정밀성이 뛰어나고, 기존 치료법에 비해 부작용이 적고 치료 효과가 더 뛰어나기 때문에 인기를 얻고 있습니다. 전이성 폐 선암의 경우, 표적 치료는 암 성장에 기여하는 유전적 변이를 차단하여 환자의 생존율과 삶의 질을 개선하는 데 초점을 맞추고 있습니다. 예를 들어, 2023년 7월 미국 유전자 및 세포 치료학회(ASGCT)와 Citeline은 2023년 2분기 말까지 제2상 임상 시험에 진입한 유전자 치료제의 수가 5% 증가해 260개를 기록했다고 보고했습니다. 표적 치료법의 사용 증가가 시장 확대에 기여하고 있습니다.
전이성 폐 선암 치료 시장 기업들은 특정 유전적 변이를 표적화해 장기 생존율과 환자 예후를 개선하기 위해 화학요법 없는 치료법 개발에 집중하고 있습니다. 화학요법 없는 옵션인 표적 치료와 면역 요법은 전통적 화학요법의 심각한 부작용을 줄이면서 암을 효과적으로 관리하는 것을 목표로 합니다. 예를 들어, 2024년 8월 존슨앤드존슨은 미국 식품의약국(FDA)이 특정 EGFR 변이를 가진 전이성 비소세포폐암(NSCLC)에 대한 첫 번째 화학요법 없는 치료제로 RYBREVANT(amivantamab-vmjw)와 LAZCLUZE(lazertinib)의 병용 요법을 승인했다고 발표했습니다. 이 승인은 Phase 3 MARIPOSA 연구 결과를 기반으로 하며, 이 연구에서는 오시머티닙 대비 무진행 생존 기간이 개선된 것으로 나타났습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 전이성 폐 선암 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 전이성 폐 선암 치료 시장 : 성장률 분석
- 세계의 전이성 폐 선암 치료 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 전이성 폐 선암 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 전이성 폐 선암 치료 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 전이성 폐 선암 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 화학요법
- 표적 치료
- 면역요법
- 방사선 치료
- 세계의 전이성 폐 선암 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 정맥내
- 세계의 전이성 폐 선암 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 암 연구센터
- 전문 클리닉
- 세계의 전이성 폐 선암 치료 시장 : 화학요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 백금 제제 화학요법
- 비백금 제제 화학요법
- 병용 요법
- 단제화학요법
- 세계의 전이성 폐 선암 치료 시장 : 표적 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 상피 성장 인자 수용체 억제제
- 미분화 림프종 키나아제 억제제
- C-Ros 종양 유전자 1 수용체 티로신 키나아제 억제제
- V-Raf 쥐 육종 바이러스 종양 유전자 동종 B1 억제제
- 형질 도입 중 재배열 억제제
- 중간엽-상피 전이 인자 억제제
- 신경영양 트로포미오신 수용체 키나아제 억제제
- 세계의 전이성 폐 선암 치료 시장 : 면역요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- PD-1 억제제
- PD-L1 억제제
- CTLA-4 억제제
- 병용 면역요법
- CAR-T 세포 요법(신흥)
- 세계의 전이성 폐 선암 치료 시장 : 방사선 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 외부 방사선 치료(EBRT)
- 정위 방사선 치료(SBRT)
- 강도 조절 방사선 치료(IMRT)
- 양자선 치료
제7장 지역별, 국가별 분석
- 세계의 전이성 폐 선암 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 전이성 폐 선암 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 전이성 폐 선암 치료 시장 : 경쟁 구도
- 전이성 폐 선암 치료 시장 : 기업 프로파일
- Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bayer AG
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Astellas Pharma Inc.
- Exelixis
- BeiGene Ltd.
- Novocure
- Blueprint Medicines Corporation
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 전이성 폐 선암 치료 시장(2029년) : 새로운 기회를 제공하는 국가
- 전이성 폐 선암 치료 시장(2029년) : 새로운 기회를 제공하는 부문
- 전이성 폐 선암 치료 시장(2029년) : 성장 전략
제36장 부록
HBR
Metastatic lung adenocarcinoma treatment involves medical strategies aimed at managing lung cancer that has spread beyond the lungs. The primary goals are to slow tumor progression, alleviate symptoms, and prolong survival. As a palliative approach, it focuses on improving the quality of life while controlling the advancement of the disease.
The main types of treatment for metastatic lung adenocarcinoma are chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells throughout the body. It is often administered intravenously or orally and can be used alone or in combination with other treatments. The primary routes of administration are oral and intravenous, and the treatment is provided by various end-users, including hospitals, cancer research centers, and specialty clinics.
The metastatic lung adenocarcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides metastatic lung adenocarcinoma treatment market statistics, including the metastatic lung adenocarcinoma treatment industry global market size, regional shares, competitors with the metastatic lung adenocarcinoma treatment market share, detailed metastatic lung adenocarcinoma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic lung adenocarcinoma treatment industry. This metastatic lung adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metastatic lung adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from$4.13 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the increasing incidence of lung cancer, the rising demand for targeted therapies, the growing adoption of immunotherapy, higher investments in oncology research, and the increasing awareness about early detection and diagnosis.
The metastatic lung adenocarcinoma treatment market size is expected to see strong growth in the next few years. It will grow to$6.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period can be attributed to the rising prevalence of smoking and environmental factors, the increasing approval of novel drug therapies, the expanding healthcare infrastructure in emerging markets, the rise in personalized medicine approaches, and the growing collaborations between pharmaceutical companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of advanced combination therapies for better outcomes, innovations in targeted drug delivery systems, progress in AI-driven diagnostics for precision treatment, and the advancement of immuno-oncology treatments.
The increasing adoption of targeted therapy is expected to drive the growth of the metastatic lung adenocarcinoma treatment market. Targeted therapy uses drugs to block cancer growth by targeting specific genes or proteins that drive tumor development and spread. This approach is gaining popularity due to its precision, as it targets specific genetic mutations, resulting in more effective treatment outcomes with fewer side effects compared to traditional therapies. For metastatic lung adenocarcinoma, targeted therapy focuses on blocking genetic mutations that fuel cancer growth, improving survival and quality of life for patients. For instance, in July 2023, the American Society of Gene and Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II trials increased by 5%, reaching 260 by the end of Q2 2023. The growing use of targeted therapies is contributing to the market's expansion.
Companies in the metastatic lung adenocarcinoma treatment market are also focusing on developing chemotherapy-free treatments that target specific genetic mutations to improve long-term survival rates and patient outcomes. Chemotherapy-free options, such as targeted therapy and immunotherapy, aim to manage cancer effectively while reducing the harsh side effects of traditional chemotherapy. For example, in August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval was based on the Phase 3 MARIPOSA study, which showed improved progression-free survival compared to osimertinib.
In January 2024, Bristol Myers Squibb (BMS) acquired Mirati Therapeutics for $4.8 billion to strengthen its cancer treatment portfolio, particularly its targeted therapies for non-small cell lung cancer (NSCLC). The acquisition supports BMS's strategy to expand its oncology pipeline and address unmet needs in cancer care. Mirati Therapeutics specializes in treatments for KRASG12C-mutated NSCLC, a critical mutation that is difficult to treat. This acquisition enhances BMS's ability to offer more precise, targeted treatments for lung cancer patients, further propelling the growth of the metastatic lung adenocarcinoma treatment market.
Major players in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, and Blueprint Medicines Corporation.
North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic lung adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the metastatic lung adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The metastatic lung adenocarcinoma treatment market consists of revenues earned by entities by providing services such as palliative and supportive care services, medical oncology services, diagnostic imaging, multidisciplinary team coordination, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic lung adenocarcinoma treatment market also includes sales of tumor-targeted radiopharmaceuticals, anti-angiogenic agents, and bispecific antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Metastatic Lung Adenocarcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on metastatic lung adenocarcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for metastatic lung adenocarcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic lung adenocarcinoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy
- 2) By Route of Administration: Oral; Intravenous
- 3) By End-User: Hospitals; Cancer Research Centers; Specialty Clinics
- Subsegments:
- 1) By Chemotherapy Drugs: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Therapy; Single-Agent Chemotherapy
- 2) By Targeted Therapy,: Epidermal Growth Factor Receptor Inhibitors; Anaplastic Lymphoma Kinase Inhibitors; C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors; V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors; Rearranged During Transfection Inhibitors; Mesenchymal-Epithelial Transition Factor Inhibitors; Neurotrophic Tropomyosin Receptor Kinase Inhibitors
- 3) By Immunotherapy: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors; Combination Immunotherapy; CAR-T Cell Therapy (Emerging)
- 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiotherapy (SBRT); Intensity-Modulated Radiation Therapy (IMRT); Proton Therapy
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Metastatic Lung Adenocarcinoma Treatment Market Characteristics
3. Metastatic Lung Adenocarcinoma Treatment Market Trends And Strategies
4. Metastatic Lung Adenocarcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Metastatic Lung Adenocarcinoma Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Metastatic Lung Adenocarcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Growth Rate Analysis
- 5.4. Global Metastatic Lung Adenocarcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Metastatic Lung Adenocarcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Metastatic Lung Adenocarcinoma Treatment Total Addressable Market (TAM)
6. Metastatic Lung Adenocarcinoma Treatment Market Segmentation
- 6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- 6.2. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- 6.3. Global Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Centers
- Specialty Clinics
- 6.4. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Chemotherapy Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Platinum-Based Chemotherapy
- Non-Platinum Chemotherapy
- Combination Therapy
- Single-Agent Chemotherapy
- 6.5. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Epidermal Growth Factor Receptor Inhibitors
- Anaplastic Lymphoma Kinase Inhibitors
- C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors
- V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors
- Rearranged During Transfection Inhibitors
- Mesenchymal-Epithelial Transition Factor Inhibitors
- Neurotrophic Tropomyosin Receptor Kinase Inhibitors
- 6.6. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- PD-1 Inhibitors
- PD-L1 Inhibitors
- CTLA-4 Inhibitors
- Combination Immunotherapy
- CAR-T Cell Therapy (Emerging)
- 6.7. Global Metastatic Lung Adenocarcinoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- External Beam Radiation Therapy (EBRT)
- Stereotactic Body Radiotherapy (SBRT)
- Intensity-Modulated Radiation Therapy (IMRT)
- Proton Therapy
7. Metastatic Lung Adenocarcinoma Treatment Market Regional And Country Analysis
- 7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Metastatic Lung Adenocarcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market
- 8.1. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Metastatic Lung Adenocarcinoma Treatment Market
- 9.1. China Metastatic Lung Adenocarcinoma Treatment Market Overview
- 9.2. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Metastatic Lung Adenocarcinoma Treatment Market
- 10.1. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Metastatic Lung Adenocarcinoma Treatment Market
- 11.1. Japan Metastatic Lung Adenocarcinoma Treatment Market Overview
- 11.2. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Metastatic Lung Adenocarcinoma Treatment Market
- 12.1. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Metastatic Lung Adenocarcinoma Treatment Market
- 13.1. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Metastatic Lung Adenocarcinoma Treatment Market
- 14.1. South Korea Metastatic Lung Adenocarcinoma Treatment Market Overview
- 14.2. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Metastatic Lung Adenocarcinoma Treatment Market
- 15.1. Western Europe Metastatic Lung Adenocarcinoma Treatment Market Overview
- 15.2. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Metastatic Lung Adenocarcinoma Treatment Market
- 16.1. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Metastatic Lung Adenocarcinoma Treatment Market
- 17.1. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Metastatic Lung Adenocarcinoma Treatment Market
- 18.1. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Metastatic Lung Adenocarcinoma Treatment Market
- 19.1. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Metastatic Lung Adenocarcinoma Treatment Market
- 20.1. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market
- 21.1. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market Overview
- 21.2. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Metastatic Lung Adenocarcinoma Treatment Market
- 22.1. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Metastatic Lung Adenocarcinoma Treatment Market
- 23.1. North America Metastatic Lung Adenocarcinoma Treatment Market Overview
- 23.2. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Metastatic Lung Adenocarcinoma Treatment Market
- 24.1. USA Metastatic Lung Adenocarcinoma Treatment Market Overview
- 24.2. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Metastatic Lung Adenocarcinoma Treatment Market
- 25.1. Canada Metastatic Lung Adenocarcinoma Treatment Market Overview
- 25.2. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Metastatic Lung Adenocarcinoma Treatment Market
- 26.1. South America Metastatic Lung Adenocarcinoma Treatment Market Overview
- 26.2. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Metastatic Lung Adenocarcinoma Treatment Market
- 27.1. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Metastatic Lung Adenocarcinoma Treatment Market
- 28.1. Middle East Metastatic Lung Adenocarcinoma Treatment Market Overview
- 28.2. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Metastatic Lung Adenocarcinoma Treatment Market
- 29.1. Africa Metastatic Lung Adenocarcinoma Treatment Market Overview
- 29.2. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Metastatic Lung Adenocarcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Metastatic Lung Adenocarcinoma Treatment Market Competitive Landscape And Company Profiles
- 30.1. Metastatic Lung Adenocarcinoma Treatment Market Competitive Landscape
- 30.2. Metastatic Lung Adenocarcinoma Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Metastatic Lung Adenocarcinoma Treatment Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Sanofi S.A.
- 31.3. Bristol-Myers Squibb Company
- 31.4. AstraZeneca PLC
- 31.5. Novartis AG
- 31.6. GlaxoSmithKline plc
- 31.7. Takeda Pharmaceutical Company Limited
- 31.8. Eli Lilly and Company
- 31.9. Amgen Inc.
- 31.10. Boehringer Ingelheim International GmbH
- 31.11. Astellas Pharma Inc.
- 31.12. Exelixis
- 31.13. BeiGene Ltd.
- 31.14. Novocure
- 31.15. Blueprint Medicines Corporation
32. Global Metastatic Lung Adenocarcinoma Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Metastatic Lung Adenocarcinoma Treatment Market
34. Recent Developments In The Metastatic Lung Adenocarcinoma Treatment Market
35. Metastatic Lung Adenocarcinoma Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Metastatic Lung Adenocarcinoma Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
